drugset

drugset / Trial / NCT03887026

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

NCT03887026 ↗

Phase 2 Completed 36 enrolled Emergo Therapeutics, Inc.

RandomizedCrossoverQuadruple-blindTreatment

Summary

This is a Phase 2a study to evaluate the efficacy and safety of Norketotifen (NKT) in subjects with allergic rhinitis.

Timeline

Start: 2019-04-01
Primary completion: 2019-05-18
Completion: 2019-05-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Norketotifen	Small molecule	—	Oral

Indications